TGM3 and cholangiocarcinoma: Compared to the respective normal groups, TGM3 expression was higher in the cancer groups, including uterine corpus endometrial carcinoma (UCEC), kidney renal papillary cell carcinoma (KIRP), pan-kidney cohort (KIPAN), colon adenocarcinoma (COAD), prostate adenocarcinoma (PRAD), colon and rectum adenocarcinoma (COADREAD), kidney renal clear cell carcinoma (KIRC), lung squamous cell carcinoma (LUSC), liver hepatocellular carcinoma (LIHC), high-risk Wilms tumor (WT) and cholangiocarcinoma (CHOL).